Richard Forman

Richard D. Forman is currently the managing partner of Health Venture Group, LLC a private investment company focused on technology and consumer related health care investments.  He is also a co-founder of Vitals.Com, one of the leading healthcare IT companies focused on transparency and cost-savings.  Vitals has been funded with over $85 million including its most recent round led by Goldman Sachs.  He has a history of investing in early stage companies and providing hands on efforts to grow these companies into sustainable entities with long term value for shareholders.

He is also an investor in other health care companies including Centrihealth (sold to UnitedHealthcare for more than $300 million) , Startup Health, Blueprint Health, Maxwell Health and

Mr. Forman is a board member for Maimonides Medical Center (“MMC”), the leading treatment facility and academic medical center in Brooklyn, NY.  MMC has approximately $1.2 billion in revenue; annually serves over 50,000 patient discharges, over 150,000 emergency room visits; and has over 1,000 staff physicians. 

Previously, Mr. Forman was co-Founder, President and CEO of, Inc. (NASDAQ-RCOM) through June of 2003.  During his tenure, Mr. Forman led the Company through explosive growth and change including

  • Grew revenue to over $115mm

  • Successfully completed three (3) acquisitions, including one cross-border EU based acquisition

  • Raised over $150mm through a series of private and public (IPO) offerings of preferred and common stock

  • Generated $100mm in cumulative operating cash flows and achieved 12 quarters of positive operating cash flow

  • Received the Ernst & Young Entrepreneur of the Year Award (Winner in 2002 and a Finalist in 2000)

In addition, Mr. Forman was instrumental in deregulating the domain name market.  Mr. Forman assisted the industry and the Department of Commerce in delegating its internet responsibilities to the Internet Corporation for Assigned Names and Numbers (ICANN). 

Also, Mr. Forman was a consultant with Booz & Company, the oldest and one of the leading international management consulting firms.  At the firm, he worked out of the New York, NY and Sydney, Australia offices and consulted on systems, operations and strategy assignments. 

Mr. Forman is a Cum Laude graduate of the University of Pennsylvania's Management and Technology Program where he earned a B.S. in Economics from the Wharton School and a B.S. in Electrical Engineering from the Moore School. He also obtained a Masters Degree from New York University's Real Estate Institute.  Currently, he sits on the Board of Overseers for the School of Engineering at Penn.

Adam Fein, President of Pembroke Consulting, Inc.


Adam J. Fein, Ph.D., is the president of Pembroke Consulting, Inc., a management advisory and business research firm based in Philadelphia. He also is the CEO of Pembroke’s Drug Channels Institute, a leading management educator for and about the pharmaceutical industry.

Dr. Fein is one of the country’s foremost experts on pharmaceutical economics and the drug distribution system. Top manufacturers call on Dr. Fein’s insights and judgment, to create successful commercial strategies and make better strategic decisions in our evolving healthcare environment.

Dr. Fein’s popular and influential Drug Channels blog is the go-to source for definitive and comprehensive industry analysis, delivered with a witty edge. He has published hundreds of academic and industry articles, and is regularly quoted in such national publications as The Wall Street JournalThe New York TimesForbes, and many others.

Dr. Fein also is a popular speaker. He inspires his audiences to think strategically with content-rich and entertaining keynote presentations.

Dr. Fein earned his doctoral degree from the Wharton School of Business at the University of Pennsylvania and a B.A., summa cum laude, from Brandeis University. He lives in Philadelphia with his wife and their two children.

Joel Freedman, Chairman of Paladin Healthcare Capital and Management

Joel Freedman (002).jpg

Joel Freedman is majority shareholder and Chairman of Paladin Healthcare Capital, which invests in, lends to, and acquires underperforming health care companies; and Paladin Healthcare Management, which manages several community hospitals, including Howard University Hospital in Washington, DC. He also serves as President and Co-Founder of Avanti Hospitals, which owns and operates four hospitals in South and East Los Angeles. Before establishing Avanti, he served as Managing Partner of Paladin Capital and co-founded CompWest Insurance Company. In his role as Chairman of Paladin, Mr. Freedman has been the principal architect of Paladin’s recently announced acquisition of Philadelphia-based Hahnemann University Hospital, St. Christopher’s Hospital for Children, several affiliated physician practices, and all related real property.  Hahnemann and St. Christopher’s serve as the primary teaching hospitals for The Drexel University College of Medicine and have rich histories of providing quality care to the greater Philadelphia area. Mr. Freedman is a founding member of the Healthcare Policy Advisory Council at Harvard Medical School, current Chairman of the Industry Work Group for Harvard’s Healthcare Markets and Regulation Lab, and serves on the Board of the Leonard D. Schaeffer Center for Health Policy and Economics at the University of Southern California.

John Bermel, Chief Financial Officer of Healthfirst


Mr. Bermel has been the CFO of Healthfirst since February 2016, bringing more than 20 years of health care industry experience to his role. Healthfirst is the largest not-for-profit health plan in New York City and in New York State with over $10.5 billion in revenue and 1.35 million members.  Through several broad roles, John has demonstrated success in financial management, turnaround and change management and as a trusted advisor to executive management. John spent 17 years at Aetna where he began as Controller of the Health Business and then was the CFO for Business Operations, serving as the company’s Senior Business Unit Finance Officer for the large part of his tenure. John was a key member of the management team responsible for the historic turnaround of Aetna.  Prior to joining Aetna, John served as Controller of Insurance Operations at United Healthcare and as Controller of MetraHealth, which United Healthcare purchased. He also spent over 11 years in public accounting serving insurance clients. John holds a Bachelor of Science in Business Administration from Georgetown University and a Masters of Business Administration in Finance from The Wharton School (WEMBA).


Brian G. Murphy, General Partner at NewSpring Health Capital

Brian Murphy.jpg

Mr. Murphy is a General Partner of NewSpring Health Capital, General Partner of NewSpring Ventures, and a Partner of NewSpring Capital, with more than 25 years of corporate management and development experience, focused primarily in healthcare services.  He has a strong background in business strategy, investment structuring, organizational growth, and negotiation of mergers and acquisitions.  Prior to NewSpring, he founded Acquisition Management Services, Inc. (AMS), a diversified corporate development advisory firm focusing on middle market companies.  AMS closed more than 330 acquisitions for its buy side clients.  He has also founded two venture-backed startups, WordWave, a legal court reporting and broadcast captioning leader (later sold to Merrill Corp.) and Precyse Solutions, a provider of medical transcription and health information services to acute care hospitals.  Previously, he held executive positions for several healthcare service companies, most notably NovaCare, Inc., Heritage Health Systems, and Partners National Health Plans.  He is currently a board member of ContinuumRx Services, SUN Behavioral Health, Verisma Systems and Seniorlink.  He is also a member of the Foundation Board of SUNY Cortland.  He received a B.S. in science from the State University of New York at Cortland.

Troy Mullane, Principal at The Boston Consulting Group

Troy Mullane.jpg

Troy Mullane, Principal, joined The Boston Consulting Group in 2011 as an Associate. He has worked in cases across health care services, biopharma, retail, and consumer goods. His work has focused on helping our clients in a number of areas, with a focus on large-scale organizational change and sales force effectiveness. Through his work, he has helped clients to better harness digital tools and the data they have available to better serve patients in a variety of therapeutic areas.

Troy holds a BS in Business Administration from the University of North Carolina, where he concentrated in International Business.


Curtis Duggan, CEO and Co-Founder of Blue Mesa Health


Curtis Duggan is the CEO and Co-Founder of Blue Mesa Health. Coming from a background as an agency owner in the field of technology, mobile product development, and user experience design, Curtis is now tackling one of the world’s most pressing health problems: the burden posed by lifestyle-related and chronic disease.

While co-founding and running Dactyl Studios, his British Columbia-based mobile app agency, for four years, Curtis saw firsthand how profoundly the mobile and cloud revolutions were transforming various industries in the early 2010s. However, he observed that the health care industry in particular was not leveraging advances in technology and experience design with the same velocity as other industries. In 2015, he decided to dedicate his life to addressing the global chronic disease burden by partnering with co-founders and investors to co-create Blue Mesa Health, a digital health company with a mission to provide chronic disease prevention solutions in the USA and internationally.

Blue Mesa Health delivers Transform and Transformemos, English- and Spanish-language digital translations of the CDC’s landmark preventive program, the Diabetes Prevention Program.


Mansur Shomali, MD, CM, Medical Director, WellDoc, Inc. and Endocrinology Faculty Member, MedStar Union Memorial Hospital

Dr. Mansur Shomali.jpg

Mansur E. Shomali, MD, CM, has served as medical director for the diabetes technology company WellDoc since 2012, where he oversees many of the clinical aspects of the company’s diabetes products. While at WellDoc, Dr. Shomali’s responsibilities have included directing product development and innovation, supporting the quality systems and regulatory strategies, directing research and data science activities, and presenting to payers as well as external stakeholders.  He also actively takes care of patients with diabetes, obesity, and other endocrine and metabolic conditions at MedStar Union Memorial Hospital in Baltimore, Maryland, where he sees patients two days per week. Dr. Shomali also maintains an academic affiliation at the University of Maryland School of Medicine where he has the rank of clinical associate professor and has served as instructor of medicine at The Johns Hopkins University School of Medicine, where he enjoys teaching medical students and physicians-in-training.

Dr. Shomali completed an undergraduate degree in biomedical engineering at The Johns Hopkins University. He received his medical degree from McGill University in Montreal, Canada and completed an internship and a residency in internal medicine at the University of Maryland School of Medicine. Subsequently he completed fellowships in endocrinology and metabolism at Massachusetts General Hospital and Harvard Medical School in Boston, Massachusetts. He is certified by the American Board of Internal Medicine in endocrinology, diabetes, and metabolism.

Dr. Shomali has a research interest in novel ways to treat individuals with type 2 diabetes. He has served as principle investigator for numerous clinical trials of novel pharmacologic agents as well as investigator-initiated studies examining the improvement of care for individuals with diabetes. His expertise is in complex pharmacologic approaches and in the use of technology in healthcare. He has published over 30 peer-reviewed medical articles and textbook chapters, has served on several journal editorial boards, and has given hundreds of scientific and educational presentations. Currently Dr. Shomali is an active member of the American Association of Clinical Endocrinology and the American Diabetes Association.

Piotr Gorecki, MD, FACS, Chief of Laparoscopy and Medical Director of Bariatric and Metabolic Surgery Center at New York Methodist Hospital

Dr. Piotr Gorecki.jpg

Piotr Gorecki, M.D., F.A.C.S., F.A.S.M.B.S is a board-certified surgeon and a Director of Bariatric and Metabolic Surgery Center at the New York-Presbyterian Brooklyn Methodist Hospital. He also is an Associate Professor of Clinical Surgery at Weill Medical College of Cornell University. Dr. Gorecki completed a special fellowship in advanced laparoscopic surgery at the Mayo Clinic. His training included a variety of innovative and advanced laparoscopic surgical techniques. Dr. Gorecki has been involved in the development of new laparoscopic techniques and in teaching them to other surgeons. His clinical and research interest has been focused on minimally invasive treatment of morbid obesity, metabolic syndrome and diabetes. He was one of the first surgeons in the region to utilize these techniques and has some of the largest experience in the country in doing so.

For more information, please visit

See Dr. Gorecki's CV for more information about his background.  

Jeffrey Bechtel, Senior Vice President for Health Economics and Policy for The Hospital & Healthsystem Association of Pennsylvania

Jeff Bechtel.JPG

Jeffrey W. Bechtel is Senior Vice President for Health Economics and Policy for The Hospital & Healthsystem Association of Pennsylvania (HAP). In this capacity, Mr. Bechtel is responsible for leading HAP’s policy development process and serving as the primary liaison with the Medicaid program on health care delivery and financing.

Prior to his role with HAP, Mr. Bechtel was the owner of Bechtel Healthcare Consulting LLC, where he provided consulting and policy support to all physical health managed care organizations (MCOs) that participate in HealthChoices, Pennsylvania’s mandatory Medicaid Managed Care Program. In this role, Mr. Bechtel worked with MCO senior leadership to develop policy recommendations relating to major Commonwealth initiatives. 

Before entering the private sector, Mr. Bechtel had 14 year career with the Commonwealth’s Department of Public Welfare (now known as the Department of Human Services). Among other roles, Mr. Bechtel served as Director of the Bureau of Managed Care Operations, where he was responsible for administering the HealthChoices Medicaid managed care program in Pennsylvania. He also served as Director of the Bureau of Program Integrity, the office responsible for administering a multi-faceted statewide program to protect the financial integrity of Pennsylvanian’s Medicaid Program. Prior to these management roles, Mr. Bechtel served as an attorney in the Department of Public Welfare’s Office of Legal Counsel and in private practice. 

Mr. Bechtel holds a Bachelor of Arts degree in Economics and Government from the College of William and Mary, and a Juris Doctor, cum laude, from The George Washington University National Law Center.

Dr. James Wilson, Director of Penn's Orphan Disease Center


James M. Wilson, MD, PhD, is the Director of the Orphan Disease Center at the University of Pennsylvania. Dr. Wilson began his work in gene therapy during his graduate studies at the University of Michigan over 30 years ago. He created the first and largest academic-based program in gene therapy after being recruited to Penn in 1993. He initially focused on the clinical translation of existing gene transfer technologies but soon redirected his efforts to the development of second and third generation gene transfer platforms; the first of which was licensed to a biotechnology company he founded that resulted in the first, and only, commercially approved gene therapy in the western hemisphere.  He is currently leading a national dialogue on the challenges of commercializing these potentially lifesaving treatments due to the disruptive nature they will have on traditional business models. Dr. Wilson was noted by the journal Nature Biotechnology to be the “second most productive bio-entrepreneur in life sciences.”


Sally Poblete, CEO and Founder of Wellthie

Sally Poblete Headshot.jpg

Sally is the chief visionary, growth officer, insurance geek, and cheerleader at Wellthie.  She spends most of her time listening to customers, envisioning new ideas, and building the best team.  She envisions a future world where purchasing insurance is a satisfying and confident experience.

Prior to starting Wellthie, Sally spent close to a decade as an executive at Anthem BlueCross BlueShield where she led product development and launched large enterprise initiatives across the country.  With a builder’s DNA,  Sally spent the first decade of her career wearing business development, marketing, and product hats at successful start-ups like Medscape and another insurance start-up Healthmarkets.

Sally received her MBA from the Wharton School’s Health Care Management program where is an active alumna and mentor.  She received her B.S. in Management magna cum laude from the Stern School of Business of New York University.

She is the proud mother of two strong daughters from whom she derives endless inspiration.

Dr. Aditi Sen, Health Economist and Professor at the Johns Hopkins Bloomberg School of Public Health


Aditi P. Sen is a health economist and assistant professor in the Department of Health Policy and Management at the Johns Hopkins Bloomberg School of Public Health. Her research addresses the potential of innovative payment and delivery models, as well as insurance design, to improve the quality and value of health care. In addition, her research seeks to apply insights from behavioral economics to understand provider and consumer behavior. From 2015-16, she was a Health and Aging Policy Fellow in the Office of the Assistant Secretary for Planning and Evaluation at the U.S. Department of Health and Human Services. She also served for a year on the staff of the White House's Council of Economic Advisers. Dr. Sen received her B.A. from Yale University and her Ph.D. in health economics from the Wharton School of the University of Pennsylvania.

Dr. Rachel Haurwitz, CEO and President of Caribou Biosciences

Haurwitz headshot.jpg

Rachel is a co-founder of Caribou Biosciences and has been President and CEO since its inception. She has a research background in CRISPR-Cas biology, and is also a co-founder of Intellia Therapeutics. In 2014, she was named by Forbes Magazine to the "30 Under 30" list in Science and Healthcare, and in 2016, Fortune Magazine named her to the "40 Under 40" list of the most influential young people in business. Rachel is an inventor on several patents and patent applications covering multiple CRISPR-derived technologies, and she has co-authored scientific papers in high impact journals characterizing CRISPR-Cas systems. Rachel earned an A.B. in Biological Sciences from Harvard College, and received a Ph.D. in Molecular and Cell Biology from the University of California, Berkeley.

Nicole Paraggio, Senior Manager at Accenture


Nicole Paraggio is a Senior Manager in Accenture’s Life Sciences Strategy practice. She has worked at fifteen life sciences clients during her almost ten year tenure at Accenture focusing most recently on digital disruption and applications of digital across the pharmaceutical value chain. In doing so she has established a unique ability to apply digital health across functional domains from Clinical to Medical to Commercial Sales & Marketing. Digital technologies that Nicole has worked with her clients to embed into their digital agendas include: augmented reality, internet of things, connected health devices, advanced analytics, and machine learning.


Prior to Accenture, Nicole received an M.S. from Duke University in Pathology where her thesis focused on vaccine immunology. Nicole also has a B.S. in both Physics and Cell & Molecular Biology from Tulane University.